Procognia

Procognia was an Israeli biotechnology company that specialized in glycobiology and the high-throughput analysis of protein glycosylation. The company developed the proprietary GlycoScope platform, which utilized lectin-based arrays to rapidly map glycan structures on therapeutic proteins, such as monoclonal antibodies and biosimilars. This technology was essential for biopharmaceutical companies to ensure the consistency and biological activity of their products during the manufacturing process. In addition to its analytical services, Procognia pursued the development of glycan-based diagnostic markers for the early detection of cancer, including a specific program for prostate cancer. Despite establishing partnerships with major pharmaceutical firms, the company faced financial difficulties and eventually ceased its primary operations.